文献
J-GLOBAL ID:201802223368127893
整理番号:18A0238995
日本人2型糖尿病患者におけるカナグリフロジン単剤療法へ追加したテネリグリプチンの有効性と安全性:多施設,無作為化,二重盲検,プラセボ対照,並行群間比較研究【Powered by NICT】
Efficacy and safety of teneligliptin added to canagliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: A multicentre, randomized, double-blind, placebo-controlled, parallel-group comparative study
著者 (10件):
Kadowaki Takashi
(Department of Diabetes and Metabolic Diseases, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan)
,
Inagaki Nobuya
(Department of Diabetes, Endocrinology, and Nutrition, Graduate School of Medicine, Kyoto University, Kyoto, Japan)
,
Kondo Kazuoki
(Ikuyaku. Integrated Value Development Division, Mitsubishi Tanabe Pharma Corporation, Tokyo, Japan)
,
Nishimura Kenichi
(Ikuyaku. Integrated Value Development Division, Mitsubishi Tanabe Pharma Corporation, Tokyo, Japan)
,
Kaneko Genki
(Ikuyaku. Integrated Value Development Division, Mitsubishi Tanabe Pharma Corporation, Tokyo, Japan)
,
Maruyama Nobuko
(Ikuyaku. Integrated Value Development Division, Mitsubishi Tanabe Pharma Corporation, Tokyo, Japan)
,
Nakanishi Nobuhiro
(Ikuyaku. Integrated Value Development Division, Mitsubishi Tanabe Pharma Corporation, Tokyo, Japan)
,
Gouda Maki
(Ikuyaku. Integrated Value Development Division, Mitsubishi Tanabe Pharma Corporation, Tokyo, Japan)
,
Iijima Hiroaki
(Ikuyaku. Integrated Value Development Division, Mitsubishi Tanabe Pharma Corporation, Tokyo, Japan)
,
Watanabe Yumi
(Ikuyaku. Integrated Value Development Division, Mitsubishi Tanabe Pharma Corporation, Tokyo, Japan)
資料名:
Diabetes Obesity & Metabolism
(Diabetes Obesity & Metabolism)
巻:
20
号:
2
ページ:
453-457
発行年:
2018年
JST資料番号:
W2549A
ISSN:
1462-8902
資料種別:
逐次刊行物 (A)
記事区分:
原著論文
発行国:
アメリカ合衆国 (USA)
言語:
英語 (EN)